Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS).
methyl salicylate | Methyl-CpG-binding domain | Poly (methyl methacrylate) | Methyl tert-butyl ether | Methyl Salicylate | Methyl salicylate | Methyl red | Methyl diethanolamine | Methyl caffeate | methyl | 4-Methyl-2-pentanol |